GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (NAS:IMRNW) » Definitions » Short-Term Debt

IMRNW (Immuron) Short-Term Debt : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Immuron Short-Term Debt?

Immuron's Short-Term Debt for the quarter that ended in Dec. 2024 was $0.00 Mil.


Immuron Short-Term Debt Historical Data

The historical data trend for Immuron's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Short-Term Debt Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Immuron Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Immuron Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Immuron Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Immuron's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuron Business Description

Traded in Other Exchanges
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.